Lingering CAR T cells may be the cause of serious gut complication after myeloma therapy
Patients with multiple myeloma who developed a serious gastrointestinal side effect after treatment with chimeric antigen receptor (CAR) T cell therapy had significantly more CAR T cells persisting in their bloodstream, according to new research from The University of Texas MD Anderson Cancer Center.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.